(VIANEWS) – CubeSmart (CUBE), Infosys Limited (INFY), Eli Lilly and Company (LLY) are the highest payout ratio stocks on this list.
We have collected information about stocks with the highest payout ratio so far. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. CubeSmart (CUBE)
137.98% Payout Ratio
CubeSmart is a self-administered and self-managed real estate investment trust. The Company's self-storage properties are designed to offer affordable, easily accessible and secure storage space for residential and commercial customers. According to the 2020 Self-Storage Almanac, CubeSmart is one of the top three owners and operators of self-storage properties in the United States.
Earnings Per Share
As for profitability, CubeSmart has a trailing twelve months EPS of $1.29.
PE Ratio
CubeSmart has a trailing twelve months price to earnings ratio of 34.82. Meaning, the purchaser of the share is investing $34.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.09%.
Moving Average
CubeSmart’s worth is under its 50-day moving average of $46.25 and higher than its 200-day moving average of $43.76.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 34.6% and a drop 26% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
CubeSmart’s EBITDA is 13.19.
Previous days news about CubeSmart (CUBE)
- According to Zacks on Wednesday, 3 May, "Investors interested in REIT and Equity Trust – Other stocks are likely familiar with Modiv Inc. (MDV Quick QuoteMDV – Free Report) and CubeSmart (CUBE Quick QuoteCUBE – Free Report) . ", "Currently, Modiv Inc. has a Zacks Rank of #1 (Strong Buy), while CubeSmart has a Zacks Rank of #2 (Buy). "
2. Infosys Limited (INFY)
56.89% Payout Ratio
Infosys Limited, together with its subsidiaries, provides consulting, technology, outsourcing, and next-generation digital services in North America, Europe, India, and internationally. It provides application management and application development services, independent validation solutions, product engineering and management, infrastructure management services, traditional enterprise application implementation, support, and integration services. The company's products and platforms include Finacle, a core banking solution; Edge suite of products; Panaya platform, Infosys Equinox, Infosys Helix, Infosys Applied AI, Infosys Cortex, and Stater digital platforms; and Infosys McCamish, an insurance platform. It serves enterprises in the financial services and insurance, manufacturing, retail, consumer packaged goods, logistics, energy, utilities, resources, services, communications, telecom OEM, media, hi-tech, and life sciences and healthcare industries. The company was formerly known as Infosys Technologies Limited and changed its name to Infosys Limited in June 2011. Infosys Limited was incorporated in 1981 and is headquartered in Bengaluru, India.
Earnings Per Share
As for profitability, Infosys Limited has a trailing twelve months EPS of $0.71.
PE Ratio
Infosys Limited has a trailing twelve months price to earnings ratio of 21.66. Meaning, the purchaser of the share is investing $21.66 for every dollar of annual earnings.
3. Eli Lilly and Company (LLY)
56.81% Payout Ratio
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $6.31.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 67.23. Meaning, the purchaser of the share is investing $67.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 62.67%.
Previous days news about Eli Lilly and Company (LLY)
- According to Zacks on Monday, 1 May, "In the year-ago quarter, ImmunoGen received license fees of $30.8 million from its license agreements with Huadong Medicine and Eli Lilly and Company (LLY Quick QuoteLLY – Free Report) ."
4. Hilltop Holdings (HTH)
35.47% Payout Ratio
Hilltop Holdings Inc. provides business and consumer banking, and financial products and services. It operates through three segments: Banking, Broker-Dealer, and Mortgage Origination. The Banking segment offers savings, checking, interest-bearing checking, and money market accounts; certificates of deposit; lines and letters of credit, home improvement and equity loans, loans for purchasing and carrying securities, equipment loans and leases, agricultural and commercial real estate loans, and other loans; and commercial and industrial loans, and term and construction finance. This segment also provides treasury management, wealth management, asset management, check cards, safe deposit boxes, online banking, bill pay, trust, and overdraft services; and estate planning, management and administration, investment portfolio management, employee benefit accounts, and individual retirement accounts, as well as automated teller machines. The Broker-Dealer segment offers public finance services that assist public entities in originating, syndicating, and distributing securities of municipalities and political subdivisions; specialized advisory and investment banking services; advice and guidance to arbitrage rebate compliance, portfolio management, and local government investment pool administration; structured finance services, which include advisory services for derivatives and commodities; sells, trades in, and underwrites U.S. government and government agency bonds, corporate bonds, and municipal bonds, as well as mortgage-backed, asset-backed, and commercial mortgage-backed securities and structured products. This segment also provides asset and liability management advisory, clearing, retail, and securities lending services. The Mortgage Origination segment offers mortgage, jumbo, Federal Housing Administration, Veterans Affairs, and United States Department of Agriculture loans. Hilltop Holdings Inc. was founded in 1998 and is headquartered in Dallas, Texas.
Earnings Per Share
As for profitability, Hilltop Holdings has a trailing twelve months EPS of $1.72.
PE Ratio
Hilltop Holdings has a trailing twelve months price to earnings ratio of 17.6. Meaning, the purchaser of the share is investing $17.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.37%.
Moving Average
Hilltop Holdings’s value is below its 50-day moving average of $30.40 and above its 200-day moving average of $29.21.
